Arvinas ARVN
NASDAQ ARVN
$6.82 -0.09 (-1.23%)
As of: Nov 12, 2026 · 11:47 AM EST

Arvinas (ARVN) Cost of Revenue (2026)

Updated

Analysis

Arvinas (ARVN) Cost of Revenue (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 3.93 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 8.10 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.29 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.89 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 2.95 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.79 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.57 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.03 Bn
10 Arvinas 453.26 Mn -1.97 Bn 400,000.00 100,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 100,000.00
Jun 30, 2026 9.00 Mn
API Access

Arvinas Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=ARVN&period=max&api_key=YOUR_API_KEY